First-in-Human Trials Demand a New Standard of Administrative Precision
Phase I first-in-human (FIH) studies represent some of the most operationally demanding work in drug development. A single FIH oncology dose-escalation trial may involve 30 to 60 patients across multiple cohorts, a safety review committee (SRC) or dose-escalation committee (DEC) that convenes after every cohort to assess tolerability, and a clinical pharmacy team managing investigational drug accountability across multiple dosing cycles—all running simultaneously.
According to the Tufts Center for the Study of Drug Development, the average cost to develop a new drug exceeded $2.6 billion in 2023, with Phase I representing an increasingly large share of total development investment as sponsors pursue complex oncology, gene therapy, and cell therapy programs. Any administrative delay in a FIH program—a missed DEC data cut deadline, a clinical pharmacy accountability discrepancy, a scheduling breakdown for sentinel dosing—can ripple forward into Phase II timelines and regulatory submissions.
CROs and academic Phase I units are turning to virtual assistants to absorb the high-volume, time-sensitive administrative work that surrounds these studies, freeing clinical research associates (CRAs) and study coordinators for protocol-facing responsibilities.
Dose Escalation Scheduling: Where Administrative Errors Are Costliest
In a traditional 3+3 or accelerated dose-escalation design, cohort advancement depends on completing a defined observation period for all enrolled patients and convening the DEC to review safety data. The scheduling chain is precise: last patient in a cohort must complete their DLT observation window, safety data must be compiled and distributed to DEC members in advance, and the committee meeting must be scheduled to allow cohort-opening decisions in time to maintain enrollment continuity.
A virtual assistant can own the scheduling layer of this workflow: maintaining a dose-escalation milestone calendar, tracking each patient's DLT observation window end date, sending reminders to the clinical team for data entry completeness, coordinating DEC member availability, and distributing meeting logistics and pre-read packages. When the DEC convenes, the VA ensures that minutes templates, voting records, and cohort-advancement documentation are captured and filed to the Trial Master File (TMF) within required timeframes.
Safety Data Cut Preparation: Compiling the Package That Drives Decisions
Data Safety Monitoring Boards (DSMBs), SRCs, and independent DEC committees all require structured data packages to make dose-escalation or stopping decisions. These packages typically include patient listings for adverse events, laboratory values, vital signs, and dose modifications—pulled from EDC systems, clinical pharmacology databases, and site-reported data in combination.
The preparation of these packages often falls to data management or clinical operations staff who are already fully loaded with ongoing monitoring responsibilities. Virtual assistants can take on the coordination layer: tracking which data fields must be locked before the cut date, sending queries to site staff for missing data, assembling the finalized dataset for biostatistics review, and organizing the output documents into the package template required by the DSMB or SRC charter.
Clinical Pharmacy Coordination: Managing Investigational Product Logistics
Phase I FIH studies, particularly in oncology and rare disease, frequently involve complex investigational medicinal product (IMP) logistics. Drug may be supplied in limited quantities tied to individual synthesis batches, requiring precise accountability tracking. Temperature-controlled storage, chain-of-custody documentation, and reconciliation between dispensing records and patient diary data all require meticulous administrative management.
A VA supporting the clinical pharmacy team can maintain the IMP accountability log, track expiry dates across multiple cohorts, coordinate drug resupply requests with the sponsor's clinical supply team, and ensure that the pharmacy accountability binders are complete and inspection-ready at all times.
CROs and academic Phase I units ready to explore this model can review healthcare-experienced VAs at Stealth Agents.
With Phase I complexity increasing as gene therapies, ADCs, and bispecific antibodies enter FIH testing, the administrative infrastructure supporting these programs must be as precise as the science driving them.
Sources
- Tufts Center for the Study of Drug Development. Cost of Developing a New Drug. csdd.tufts.edu
- ICH. E6(R3) Good Clinical Practice Guideline. ich.org
- FDA. Guidance for Industry: Oversight of Clinical Investigations. fda.gov